Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.8350
+0.0157 (1.92%)
Jul 29, 2026, 1:59 PM EDT - Market open
RANI Revenue
Rani Therapeutics Holdings had revenue of $1.71M in the quarter ending March 31, 2026, with 893.02% growth. This brings the company's revenue in the last twelve months to $3.17M, up 164.08% year-over-year. In the year 2025, Rani Therapeutics Holdings had annual revenue of $1.63M with 58.85% growth.
Revenue (ttm)
$3.17M
Revenue Growth
+164.08%
P/S Ratio
32.03
Revenue / Employee
$44,634
Employees
71
Market Cap
103.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.63M | 605.00K | 58.85% |
| Dec 31, 2024 | 1.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 2.72M | 2.26M | 488.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Fortress Biotech | 66.16M |
| Gossamer Bio | 55.54M |
| Verrica Pharmaceuticals | 37.16M |
| ImmuCell | 29.93M |
| Pelthos Therapeutics | 27.70M |
| Coya Therapeutics | 7.94M |
| NeOnc Technologies Holdings | 39.99K |
RANI News
- 8 days ago - Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Rani Therapeutics reports initial data from RT-114 study - TheFly
- 14 days ago - Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing - GlobeNewsWire
- 19 days ago - Rani Therapeutics announces research, development collaboration with PegBio - TheFly
- 19 days ago - Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates - GlobeNewsWire
- 4 weeks ago - Rani Therapeutics appoints Nicholas Maestas as CFO - TheFly
- 4 weeks ago - Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Rani Therapeutics Holdings Transcript: AGM 2026 - Transcripts